ResearchMoz presents professional and in-depth study of "Competitor Landscape: Atopic Dermatitis".
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978214
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Key Highlights
- AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD
- Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US
- Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population.
Scope
- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/competitor-landscape-atopic-dermatitis-report.html/toc
Reasons to buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharmas Competitor Landscape
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Lifecycle Development
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978214
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Sociable Pharmas Treatment Landscape contains evaluations of ongoing development activities within the Atopic Dermatitis (AD) market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher -
- Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharmas view of the disease landscape
Get Free PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1978214
- Landscape Updates: Order of Entry analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved products lifecycle management initiatives; Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies
- Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
- Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Key Highlights
- AT-502 is the second topical JAK inhibitor in development for atopic dermatitis behind ruxolitinib/ INCB018424, however is the only topical JAK inhibitor targeting moderate-to-severe AD
- Upadacitinib and baricitinib are competing to the first-in-class JAK inhibitor approved for AD, with upadacitinib likely approved a quarter before baricitinib in the US
- Data for PF-04965842's adolescent trial will likely be released in Q4 2019, and along with data from JADE Mono-1, will be the basis for filing in the adolescent patient population.
Scope
- The briefing is based on Sociable Pharmas analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
- Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
- Forecasts are presented in pipeline forecast figures & detailed tables
- Market Entry & Direction of Travel positioning analysis for pipeline & currently approved therapies is also provided.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/competitor-landscape-atopic-dermatitis-report.html/toc
Reasons to buy
- Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
- Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
- Reviews ongoing lifecycle management strategies for existing players in the market
- A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Table of Contents
Introduction to Sociable Pharmas Competitor Landscape
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Lifecycle Development
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1978214
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
No comments:
Post a Comment